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Abstract 
The AMP-activated protein kinase (AMPK) is a sensor of cellular energy status expressed in 
essentially all eukaryotic cells. Once activated by energetic stress via a mechanism that detects 
increases in AMP:ATP and ADP:ATP ratios, AMPK acts to restore energy homeostasis by 
switching on catabolic pathways that generate ATP, while switching off ATP-consuming processes, 
including anabolic pathways required for cell growth and proliferation. AMPK activation promotes 
the glucose-sparing, oxidative metabolism utilized by most quiescent cells, rather than the rapid 
glucose uptake and glycolysis used by most proliferating cells. Numerous pharmacological 
activators of AMPK are known, including drugs in long use such as salicylate and metformin, and 
there is evidence that regular use of either of the latter provides protection against development of 
cancer. Tumor cells appear to be under selection pressure to down-regulate AMPK, thus limiting its 
restraining influence on cell growth and proliferation, and several interesting mechanisms by which 
this occurs are discussed. Paradoxically, however, a complete loss of AMPK function, which 
appears to be rare in human cancers, may be deleterious to survival of tumor cells. AMPK can 
therefore either be a friend and a foe in cancer, depending on the context. 
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Background 
The AMP-activated protein kinase (AMPK) is a sensor of cellular energy status and a key regulator 
of energy homeostasis, which exists universally in eukaryotes as heterotrimeric complexes 
containing catalytic α and regulatory β and γ subunits (1, 2). In mammals, there are multiple 
isoforms of each subunit (α1, α2; β1, β2; γ1, γ2, γ3) encoded by distinct genes, generating up to 
twelve heterotrimeric combinations. In the yeast Saccharomyces cerevisiae, the AMPK ortholog is 
required for the response to glucose starvation, especially for the switch from rapid growth in high 
glucose using fermentative metabolism (i.e. glycolysis) to the slower growth using oxidative 
metabolism that occurs when glucose becomes limiting (3). This metabolic switch is equivalent to 
reversal of the “Warburg effect” that occurs in many rapidly proliferating mammalian cells, 
including tumor cells. 
 ATP and ADP can be likened to the chemicals in a rechargeable battery, with a high ratio of 
ATP:ADP representing a fully charged cellular “battery”, while any decrease indicates that the 
battery is becoming flat. Because the reaction catalyzed by adenylate kinase (2ADP ↔ ATP + 
AMP) operates close to equilibrium in most eukaryotic cells, any increase in ADP:ATP is always 
accompanied by a much larger rise in AMP:ATP (4), making the latter ratio a particularly sensitive 
indicator of energy stress. AMPK monitors cellular energy status by detecting increases in these 
ratios. In all species, it is activated >100-fold by phosphorylation of a conserved threonine residue 
(Thr172 in rat α2 (5)) located within the “activation loop” of the α subunit kinase domain.  The 
primary upstream kinase phosphorylating this site in mammalian cells is a complex comprising the 
protein kinase LKB1 and two accessory subunits, STRAD and MO25 (6). Heterozygous mutations 
in STK11, the human gene encoding LKB1, had been identified as the cause of Peutz-Jeghers 
syndrome, an inherited susceptibility to cancer (7, 8). Thus, LKB1 is a tumor suppressor, and the 
findings that it acted upstream of AMPK introduced the first link between AMPK and cancer. 
 The γ subunits of AMPK contain three binding sites for AMP, with ADP and ATP binding in 
competition with AMP, at least at two of them (9, 10). AMP binding activates AMPK by three 
distinct mechanisms: (i) increased Thr172 phosphorylation by LKB1; (ii) decreased Thr172 
dephosphorylation by protein phosphatases; (iii) allosteric activation (>10-fold) (11) (Fig. 1). This 
tripartite mechanism makes the system an exquisitely sensitive sensor of cellular energy status. 
Effects (i) and possibly (ii), but not (iii), are mimicked by binding of ADP, while all three are 
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antagonized by ATP (11-13). All three are due to binding of AMP to AMPK itself, rather than to 
the upstream kinase or phosphatase. Thus, although LKB1 normally has to be present for cellular 
energy stress to activate AMPK, it is not itself activated by it (14). An alternate upstream kinase 
phosphorylating Thr172, the calmodulin-dependent kinase CaMKKβ, is only active in cells when 
intracellular Ca2+ has been elevated (Fig. 1). This alternate, AMP-independent pathway mediates 
the effects of hormones that use Ca2+ as second messenger (15, 16). 
 Once activated by energy stress, AMPK acts to restore energy homeostasis by promoting 
catabolic pathways generating ATP, while inhibiting ATP-consuming processes (1). The latter 
include most anabolic pathways, including those promoted by the mechanistic target-of-rapamycin 
complex-1 (mTORC1) signaling pathway, which is inhibited by AMPK (17, 18). Since AMPK 
switches off the synthesis of lipids, RNAs and proteins, it inhibits cell growth. It also causes a G1 
cell cycle arrest by promoting phosphorylation of p53, thus blocking DNA synthesis (19, 20). 
Although AMPK can acutely enhance glucose uptake and glycolysis in some cell types, in the 
longer term it promotes (like its yeast ortholog) the more glucose-sparing, mitochondrial oxidative 
metabolism used by quiescent cells, rather than the rapid glucose uptake, glycolysis and pentose 
phosphate pathway used predominantly by proliferating cells (21). 
 Numerous pharmacological agents that activate AMPK have been identified, including many 
natural plant products, or their derivatives, used in traditional medicines (22). These include the 
anti-diabetic biguanides metformin (23) and phenformin (6), both derived from the natural product 
galegine, as well as salicylate, the active component of willow bark of which acetyl salicylic acid 
(ASA or aspirin) is a synthetic derivative as well as a pro-drug (24). Metformin, phenformin and 
galegine, and many natural products such as resveratrol and berberine, activate AMPK indirectly by 
inhibiting mitochondrial ATP synthesis, thus increasing cellular AMP (25). However, salicylate 
activates AMPK by direct binding in a cleft between the α and β subunits, with the same site being 
used by synthetic activators such as A-769662 and 991 (26, 27). A third activation mechanism is 
exemplified by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a nucleoside taken up 
by cells and phosphorylated to the nucleotide ZMP, which mimics the effects of AMP (28). 
Interestingly, ZMP is an intermediate in the pathway of purine nucleotide biosynthesis, and is 
metabolized by a transformylase that utilizes N10-formyl-tetrahydrofolate. Some antifolates used to 
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treat cancer, including pemetrexed and methotrexate, inhibit this transformylase and thus cause 
ZMP accumulation and AMPK activation (29, 30). 
 As well as being required for activation of AMPK, LKB1 also activates a family of twelve 
AMPK-related kinases (ARKs) by phosphorylating the threonine residue equivalent to Thr172 (31). 
None of these appear to be activated by energy stress or to directly inhibit cell growth and division, 
and it therefore seems likely that most tumor suppressor effects of LKB1 are mediated by AMPK. 
However, reduced function caused by loss of LKB1 of two of the ARKs, MARK1 and MARK4, 
does contribute to increased migration and metastasis of epithelial tumor cells in mouse models 
(32). 
Clinical-Translational Advances 
 Loss of a single AMPK-α1 allele accelerates development of lymphomas induced in mice by 
transgenic expression of Myc in B cells, while loss of both alleles has an even larger effect (33). 
Although this suggests that AMPK can act as a tumor suppressor, mutations in genes encoding 
AMPK subunits appear to be rather infrequent in human cancers. This might either be because of 
redundancy between AMPK isoforms, or perhaps more likely because a low level of AMPK is 
required to maintain viability during the metabolic stresses that tumor cells often experience. In 
support of the latter, mouse embryo fibroblasts (MEFs) totally deficient in LKB1 (34) or AMPK 
(35) are resistant to transformation by mutant H-Ras, although MEFs lacking only AMPK-α2 
display increased susceptibility to transformation by mutant H-Ras in vitro, and increased growth 
as xenografts expressing mutant H-Ras in vivo (36). Thus, although a low level of AMPK function 
may be necessary for tumor cells to survive, reduction in normal expression levels may nevertheless 
promote tumorigenesis by reducing the restraining influence of AMPK on cell growth and division. 
Consistent with this, AMPK is often down-regulated in tumors by mechanisms other than somatic 
mutations. For example, immunohistochemical analysis of human breast cancer biopsies revealed 
reduced expression of AMPK-α subunits phosphorylated on Thr172, compared with surrounding 
normal tissue, in >90% of cases (37). The antibody used in this study does not distinguish between 
AMPK-α1 and -α2, and it was also not clear whether there was reduced expression of total AMPK-
α subunits. However, reduced expression of AMPK-α2 has been found to be a frequent occurrence 
in hepatocellular carcinoma, which is associated with poor prognosis (38). The mechanisms by 
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which down-regulation occurs in these cases remain unclear. One obvious mechanism is genetic 
loss of LKB1, which still allows some residual AMPK function due to the alternate 
CaMKKβ−mediated upstream pathway (15). However, while loss of LKB1 is relatively frequent in 
non-small cell lung cancer [≈30% (39, 40)] and cervical cancer [≈20% (41)], it appears to be less 
frequent in most other cancers, including breast cancer. 
 Another mechanism for down-regulation of AMPK involves the insulin/IGF1-regulated protein 
kinase Akt/PKB, which is hyper-activated in many tumors by gain-of-function mutations in 
phosphatidylinositol 3-kinases or loss-of-function mutations in PTEN. Akt phosphorylates rodent 
AMPK-α1 at Ser485 (Ser487 in humans) within a serine/threonine-rich loop (the “ST loop”) (42, 
43). This inhibits subsequent Thr172 phosphorylation and activation by LKB1 or CaMKKβ, 
because the phosphorylated ST loop interacts with the kinase domain and blocks access to Thr172 
(43). Ser487 hyper-phosphorylation occurs in several PTEN-deficient glioblastoma and breast 
cancer cell lines, and in these cells it is more difficult to activate AMPK (43). Consistent with this, 
in a mouse model in which PTEN was knocked out in thyrocytes, Ser485 phosphorylation was 
increased and Thr172 phosphorylation decreased. This was associated with thyroid gland 
hyperplasia at birth that was reduced by treatment with the AMPK activator, AICAR, and with 
occurrence of thyroid follicular adenomas by 6-8 months (44). 
 A third mechanism for AMPK down-regulation was observed in human melanoma cells carrying 
the B-Raf V600E mutation. This mutation activates B-Raf, causing activation of the downstream 
kinases Erk and RSK, which promote phosphorylation of sites in the C-terminal domain of LKB1 
that appear to reduce its ability to activate AMPK (45). Interestingly, AMPK also phosphorylates 
B-Raf at a C-terminal site (Ser729), promoting its association with 14-3-3 proteins and disrupting 
its interaction with the scaffold protein KSR1, thus exerting a reciprocal negative effect that reduces 
proliferation and cell cycle progression in keratinocytes (46). These findings may have therapeutic 
implications, because the B-Raf inhibitor PLX4720 and the AMPK activator phenformin caused 
synergistic decreases in cell viability in melanoma cells in culture, and reduced growth of human 
melanoma cells as mouse xenografts, and growth of melanomas in a genetically engineered B-
RafV600E mouse model (47). 
 Another intriguing mechanism by which AMPK is down-regulated in tumors has recently been 
reported (48). MAGE-A3 and -A6 are closely related members of the melanoma antigen family, 
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encoded by neighboring genes on the X chromosome. Like most other MAGE proteins they are 
usually only expressed in testis, but become aberrantly re-expressed in many tumors, which is 
associated with enhanced viability of the tumor cells and poor prognosis for the patient. Expression 
of MAGE-A3/–A6 in NIH-3T3 cells promoted focus formation, while expression in immortalized 
human colon epithelial cells promoted anchorage-independent growth. MAGE-A3/–A6 are known 
to interact with the E3 ubiquitin ligase TRIM28, triggering polyubiquitylation and proteasomal 
degradation of p53 (49). However, many tumor cells in which MAGE-A3/–A6 expression enhances 
viability are p53-deficient, suggesting that they must have other targets. A screen for such targets 
identified AMPK-α1, and MAGE-A3 was found to interact with AMPK-α1, targeting it for 
polyubiquitylation by TRIM28 and proteasomal degradation. Consistent with this, knocking down 
MAGE-A3/A6 in tumor cells increased expression of total and Thr172 phosphorylated AMPK-α1, 
and produced many changes in downstream signaling and metabolism expected after AMPK 
activation. Analysis of the human cancer genome atlas showed that MAGE-A3/A6 were expressed 
in 20% of colorectal adenocarcinomas, 80% of lung squamous cell carcinomas, and 25% of breast 
invasive carcinomas, and expression correlated with marked reductions of total and Thr172-
phosphorylated AMPK-α subunits, and with hyper-activation of mTORC1. Moreover, in 
immortalized human colon epithelial cells in which anchorage-independent growth was induced by 
expression of MAGE-A6, the AMPK activators AICAR and A-769662 reduced cell growth, while 
failing to do this in cells transformed with other oncogenes, such as MAGE-A10 (48). 
 A final mechanism for down-regulation of the LKB1-AMPK pathway in tumor cells involves 
microRNAs, short single-stranded RNAs that bind the 3'-untranslated regions (3'-UTRs) of specific 
mRNAs and reduce their translation into protein. One, miR-451, is over-expressed in many human 
glioblastomas. A key target for miR-451 was found to be the mRNA encoding MO25, one of the 
subunits of the LKB1 complex, and miR-451 over-expression reduced expression of MO25 and 
consequent Thr172 phosphorylation on AMPK (50). Another microRNA, miR-301a, appears to 
directly down-regulate AMPK-α1 in osteosarcoma cells (51). 
 Intriguingly, epidemiological studies in humans provide evidence that prolonged use of known 
AMPK activators provide protection against cancer development. Thus, type 2 diabetics taking 
metformin have a lower incidence of cancer (52), as do subjects taking aspirin in randomized 
control trials of its efficacy in protecting against cardiovascular events (53). It should be 
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emphasized that there is currently no direct evidence that these apparent effects are mediated by 
AMPK activation, nor that they are direct effects on the tumor cells themselves. The metformin 
studies compared diabetics taking the drug with those on other medications, which would 
particularly include sulfonylureas and insulin. Subjects with untreated Type 2 diabetes usually 
exhibit hyperinsulinemia, and metformin (due to its insulin-sensitizing effects, mediated by AMPK 
activation in the liver (54)) reduces this. By contrast, sulfonylureas enhance insulin secretion and 
thus increase plasma insulin, as does therapy with insulin itself. As insulin is a promoter of cell 
growth, reduction of hyperinsulinemia has been proposed to explain the protective effects of 
metformin in cancer. Some evidence in favor of this came from studies of human colon carcinoma 
cells grown as mouse xenografts, whose growth was reduced by treatment with metformin in mice 
that had been made insulin-resistant by feeding a high-fat diet, but not in mice on a normal chow 
diet. The same effects were observed whether or not LKB1 had been previously knocked down in 
the cells using shRNAs, suggesting that the effect of metformin was not to activate AMPK in the 
tumor cells themselves (55).  
 Although the mechanism for the apparent protective effect of metformin on the incidence of 
cancer in humans remains uncertain, the association has triggered many trials of metformin 
treatment in cancer (over 200 listed in www.clinicaltrials.gov). Many of these are small-scale pilots, 
but the MA.32 trial is recruiting >3,000 women with early stage breast cancer, who will receive 
metformin or placebo for 5 years as an adjunct to existing therapy (56). 
 Most of the pre-clinical and clinical data discussed above support the idea that AMPK is a 
“friend” in cancer, since it is a tumor suppressor down-regulated in a high proportion of cancers. 
However, tumor cells often experience metabolic stresses that occur when their growth outstrips the 
ability of their blood supply to provide oxygen and nutrients, while many cytotoxic therapies also 
cause cellular stress. As discussed above, there is evidence that a low level of AMPK may be 
necessary to maintain viability of tumor cells under these circumstances. Here, AMPK is acting as a 
“friend” to the tumor cells but a “foe” to the patient. A possible example of this was provided by a 
mouse model of non-small cell lung cancer, in which treatment with phenformin prolonged survival 
when the tumors were caused by mutant K-Ras combined with loss of LKB1, but not by mutant K-
Ras and loss of p53, where the LKB1-AMPK pathway would still be functional (57). In this 
scenario, phenformin is acting as a cytotoxic drug by inhibiting mitochondrial ATP synthesis, 
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which kills LKB1-deficient tumor cells because they lack normal AMPK function to protect them, 
unlike surrounding normal cells. 
 In another study of the LKB1-deficient A549 lung cancer cell line, glucose deprivation was 
shown to cause cell death by generating oxidative stress, but this was relieved by re-expressing 
LKB1 to restore AMPK activation. The effect of AMPK on cell survival was ascribed to its ability 
to phosphorylate and inactivate acetyl-CoA carboxylases-1 and -2 (ACC1/ACC2), thus inhibiting 
fatty acid synthesis and preserving NADPH for the reduction of oxidized glutathione to counter 
oxidative stress (58). Finally, in an shRNA screen looking for human kinases whose loss caused 
synthetic lethality when combined with over-expression of Myc, two of the hits were AMPK-α1 
and the AMPK-related kinase, Ark5/Nuak1. Although the authors chose to follow-up the latter 
rather than the former, these results suggest that AMPK-α1 is required for transformation by Myc 
over-expression (59). 
CONCLUSIONS 
Although AMPK restrains the growth and proliferation of cells, and there appears to be selection 
pressure for tumor cells to down-regulate the pathway, a low residual level of AMPK function may 
be necessary for tumor cells to overcome the nutritional and energetic stresses that often occur 
during their development. Paradoxically, therefore, while treatment with AMPK activators may 
restrain the initial growth and proliferation of tumor cells, and there is selection pressure for the 
pathway to be down-regulated, a low level of residual AMPK function may be necessary for tumor 
tissue to survive the rigors of their existence. It is possible that, in such cases, AMPK inhibitors 
might be useful as adjuncts to conventional chemotherapy in treatment of cancer. 
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Figure 1: Tripartitie mechanism for AMPK activation by 5'-AMP. AMPK is phosphorylated at 
Thr172 and activated by upstream kinases, especially the constitutively active kinase LKB1 (which 
is only active in complex with MO25 and STRAD) and the Ca2+/calmodulin-dependent kinase 
kinase, CaMKKβ. Binding of AMP to AMPK activates the kinase by three mechanisms, all of 
which are antagonized by ATP: (i) binding of AMP (and possibly ADP) promotes Thr172 
phosphorylation by LKB1; (ii) binding of AMP (and ADP at higher concentrations) inhibits Thr172 
dephosphorylation by phosphatases; (iii) binding of AMP (but not ADP) causes 10-fold allosteric 
activation. Once activated by energy stress, AMPK acts to restore energy homeostasis by activating 
catabolic pathways (including oxidative metabolism) and by inhibiting anabolic pathways 
(including those downstream of mTORC1). 
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